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Abstract 
Background 
Delay between diagnosis of peri-ampullary cancer (PC) and surgery may allow tumour 
progression and affect outcome. This study aims to explore associations of interval to surgery 
(IS) with pathological outcomes and survival in patients with PC. 
Method 
A database review of all patients undergoing surgery between 2006 and 2014 was 
undertaken. IS was measured from diagnosis by imaging. Potential association between IS 
and survival was measured using Cox regression analysis, and between IS and pathological 
outcome with multivariate logistic analysis. 
Results  
388 patients underwent surgery. The median IS was 49 days (1-551 days), and was not 
associated with any of the evaluated outcomes in patients with pancreatic (149) or distal bile 
duct (46) cancer. For patients with ampullary cancer (71) longer IS was associated with 
improved survival, with median survival of 1.3, 3.1 and 4.3 years for patients waiting <1 (9), 
1-2 (37) and >2 (25) months for surgery (p=0.036). A higher rate of margin positivity 
(31.4%) was also noted among patients who waited less than the median IS compared to 
those waiting longer than this interval (11.4%) (p=0.032). 
Conclusion 
For patients with ampullary cancer there is a paradoxical improvement in outcome among 
those with a longer IS, which may be explained by progression to inoperability of more 
aggressive lesions. 
Introduction 
Peri-ampullary cancer (PC) most commonly originates within the pancreas, the distal 
common bile duct, or the duodenal ampulla. The organ of origin of PC is usually determined 
by pathological examination after resection and has important implications for prognosis. 
Five-year survival after surgical resection varies from 6.5%-20% for pancreatic cancer (1-7), 
19.2%-30% for bile duct cancer (1, 3, 5, 6, 8, 9) and 33%-45% for ampullary cancer (1, 3, 5, 6). The 
majority of tumours are however inoperable at the time of presentation due to local invasion 
or the presence of distant metastases. For operable tumours there will usually be an interval 
between radiological diagnosis and surgery, to allow referral, assessment and operative 
planning. In England, the National Cancer Plan stipulates a maximum interval of 62 days 
from primary referral to treatment for most solid cancers (10), although this figure is not based 
on evidence of safety for each tumour type. Tumour progression may take place during this 
interval, rendering tumours inoperable due either to local invasion or the development of 
metastases, and long-term survival may be affected. 
Within any patient cohort there is likely to be a range of intervals between diagnosis and 
surgery, with some patients undergoing surgery very quickly, and some waiting many 
months. As PC is an aggressive malignancy, this period may constitute a significant part of 
the natural history of the disease. Analysis of the potential association of interval to surgery 
with pathological and surgical outcomes may reveal aspects of the behaviour of these 
tumours, and determine if the 62 day target to surgery disadvantages patients by allowing 
tumour progression. 
This study aimed to investigate the interval to surgery in a consecutive series of patients 
undergoing surgery with the intention to resect PC and to explore associations with 
resectability, tumour stage and overall survival. 
 Material and methods 
Review of a prospectively maintained database of consecutive patients undergoing surgical 
exploration for suspected PC between January 2006 and May 2014 was undertaken. Referrals 
came from five hospitals in a cancer network with a population of 1.7 million. The study 
cohort included patients with a histological diagnosis of pancreatic, bile duct or ampullary 
cancer, or those where the tumour was unresectable and biopsy confirmed the presence of 
adenocarcinoma. Patients receiving neoadjuvant chemotherapy were excluded. No patients 
were excluded from surgery due to disease progression in the interval between referral and 
surgery. Demographic and clinical data were retrieved. Pre-operative biliary obstruction was 
defined as any abnormality in liver function tests sufficient to prompt investigation by cross 
sectional imaging. As the time of receipt of the initial referral is variable and subject to 
administrative delays, the interval to surgery (IS) was measured from the date of the first 
imaging modality undertaken which raised the possible diagnosis of pancreatic head 
malignancy to the time of the surgical intervention, by review of individual radiology 
records. Surgical resection was performed by a classic Whipple resection with reconstruction 
by pancreatico-gastrostomy. Pathological reporting was undertaken according to Royal 
College of Pathologists guidelines(11) with axial slicing of the resection specimen. Tumours 
were classified according to histological origin (pancreatic, bile duct or ampullary) and nodal 
status and margin involvement status were retrieved from histology reports.  
Continuous variables were compared with Kruskal-Wallis test and categorical variables by 
Chi square test. The mean and variance of tumour size across different tumour types were 
compared using Bayesian double generalised linear models.   
Dates of death were determined by access to General Practice records and survival times 
calculated from the time of diagnosis. Kaplan-Meier survival analysis and Cox Proportional 
Hazard models were used to assess the effect of potential influence of monthly time intervals 
to surgery on post-operative survival.  Multivariate logistic models were then used to explore 
potential associations between pre-operative variables including IS as a binary variable (< or 
≥ median) with histological tumour stage.  
 
Results 
388 patients (223 males) of median age 67 years fulfilling the study criteria underwent 
surgical exploration during the study period and resection was completed in 266 cases 
(68.6%).  In 122 patients the tumour was found to be inoperable due to local invasion of 
vascular structures (70) or the development of distant metastases (47). Operative details could 
not be retrieved in three patients, tumour mass could not be identified in one patient and one 
patient did not tolerate surgery. Lateral resections of a small venous patch were undertaken in 
32 patients. The median IS for 388 patients was 49 (1-551) days, and was similar in groups 
undergoing resection (49 days, range 1-551) or surgical exploration only (50 days, range 11-
512) (P=0.940). The IS in 331 patients (85.3%) with biliary obstruction at the time of initial 
presentation was 47 days (1-512) compared to 69 (14-551) in those without this complication 
(p=0.001). Pancreatic tumours were noted to be larger than both ampullary and bile duct 
tumours (Table 1). In regression analysis the variance in size of ampullary tumours was noted 
to be greater than both pancreatic tumours (coefficient = -1.075; credible interval -1.441 to -
0.704) and bile duct tumours (coefficient = -0.63; credible interval -1.096 to -0.165).   
After minimum follow-up of 12 months the median survival (range) from diagnosis of the 
whole cohort was 17.2 months (1.4-114.6) and was significantly longer in patients 
undergoing surgical resection (23.7 months, range 1.5-114.6) compared to those having 
surgical exploration only (11.2 months, range 1.4-75.7) The median survival (range) of 
patients undergoing resection of pancreatic, bile duct and ampullary cancer was 17.3 (1.5-
114.6), 28.1 (5.8-104) and 33.3 (2.1-107.1) months respectively. No patients were lost to 
follow-up. Pre-operative IS was not associated with survival for patients undergoing resection 
of pancreatic or bile duct cancer, but a positive association was noted for patients with 
ampullary cancer (Figure 1). Cox regression analysis of survival data confirmed the reduced 
hazard of death at any time after surgery associated with a longer IS in patients with 
ampullary cancer only (Table 2). Multivariable analysis of potential associations between 
pre-operative factors and histological outcomes and survival confirms the reduced risk of 
positive resection margin in patients with a longer interval to surgery (Table 3). The 
proportion of ampullary cancer specimens removed within less than the median IS (49 days) 
with involved margins was 31%, compared to 11.4% among those removed after this interval 
from diagnosis (p=0.032).  An association between tumour size with age and female gender 
is also noted (Table 3). 
Discussion 
Patients with PC may suffer significant delays between presentation and surgery. This may be 
contributed to by the vague nature of symptoms at the time of presentation (12, 13), the need for 
biliary drainage (14), delays incurred during referral to regional centres and capacity issues 
restricting access to operating time.  Because of perceived delays in the treatment of cancer 
cases NHS guidelines introduced a target of 62 days from referral to treatment for most solid 
tumours in 2000 (10). Concerns may be raised that this delay will reduce the operability of the 
pancreatic head lesion, allow tumour progression and impair long-term survival. The main 
finding of this study is that no association is noted between delay to surgery and any outcome 
in patients with pancreatic or distal bile duct cancer, but that a longer interval to surgery is 
paradoxically associated with improved outcome in patients with ampullary cancer. A 
proportional increase in survival is noted with each extra months delay prior to surgery 
associated with a hazard ratio of death of 0.55 after surgical resection. In corroboration of this 
finding the chance of an involved resection margin is also reduced for patients with 
ampullary cancer who wait longer for surgery. 
In this series a high percentage of resected patients were shown to have ampullary cancer 
(26%). This is consistent with the adoption of a standardised pathological reporting protocol, 
which has led to higher rates of diagnoses other than pancreatic cancer in peri-ampullary 
malignancy (15, 16). PC usually presents with biliary obstruction caused by mass effect and 
operability is determined by the sequence of invasion, as vascular invasion is a major cause 
of irresectability (17-19). Lesions of the ampulla lie furthest from the vascular structures and 
may be less likely to be inoperable than lesions of the pancreatic parenchyma, which encases 
the junction between superior mesenteric and portal vein. Surgery is offered to patients who 
do not have invasion of vascular structures or distant metastases detected on pre-operative 
imaging, though these findings are often encountered at the time of surgery. This may be 
caused by understaging by CT scan (20) or by tumour progression in the interval to surgery, 
which is more likely in aggressive tumours. These results suggest that for pancreatic and bile 
duct tumours the timing of surgery in relation to pre-operative imaging within the range 
measured in the study has no effect on resectability, tumour stage or survival after resection. 
This implies that the operative findings and surgical outcome are determined before imaging 
takes place and these tumours change little in the interval to surgery. For ampullary tumours 
however it appears that a longer wait for surgery results in selection of a subset of patients 
whose tumours remain resectable, with better prognostic characteristics, as shown by the 
reduced risk of an involved resection margin and improved long-term survival. This may be 
explained by the progression of a more aggressive subset of ampullary tumours in the interval 
to surgery leading to inoperability. This more aggressive subset probably includes older 
patients, in whom resected ampullary tumours are shown to be larger. In support of this 
concept we have noted a greater variance in size of ampullary tumours than pancreatic and 
bile duct tumours. Less aggressive ampullary tumours remain confined to the region of the 
ampulla while others progress to invade vascular structures. As ampullary tumours are 
located a greater distance from the vascular structures than pancreatic and bile duct tumours 
they are likely to cause vascular obstruction as a relatively delayed event compared to biliary 
obstruction.  Results for the whole cohort however do not show an association between 
interval to surgery and resectability. It is probable that the small proportion of patients with 
ampullary cancer who progress to inoperability is masked in the larger group of patients with 
pancreatic and bile duct cancer, where IS is shown to have no effect on resectability and 
outcome.  
 In the event of inoperability usually a biopsy is taken and the presence of malignancy 
confirmed. Determining the organ of origin in this situation is difficult however, as this 
requires examination of the spatial relationship of periampullary lesions (11). Histological 
tissue stains have low specificity in determining precise tumour phenotype (21). Usually in this 
situation a diagnosis of adenocarcinoma is made and patients often referred for palliative 
treatment with chemotherapy targeted at pancreatic cancer. Our results provide indirect 
evidence that among this patient group there will also be patients with ampullary cancer 
which has progressed to involve vascular structures.  
A potential weakness of this study is the variable timing of the initial imaging. Often this was 
performed after the development of progressive jaundice, so there was an uninterrupted time 
line from presentation to surgery. In some patients however an initial presentation with 
spontaneously resolving biliary obstruction was investigated which revealed potential PC, but 
the issue was not taken forward due to clinical improvement. This presentation accounts for 
the very long IS in some patients. Although spontaneously resolving biliary obstruction has 
been reported previously in ampullary cancer (22), we have noted a similar phenomenon in 
pancreatic and bile duct cancer in this study. Another potential weakness is the lack of 
discrimination of ampullary tumours into intestinal or pancreatico-biliary phenotype. These 
two tumours have different anatomical and morphological characteristics, in addition to 
different prognosis. It is possible that the phenomenon we have observed occurs differentially 
in these two subsets. Distinguishing between these two phenotypes however does not form 
part of the Royal College of Pathologists’ dataset (11).  
Previous evidence has shown that delayed diagnosis and a prolonged interval to surgery has 
an adverse outcome in other tumour types including breast cancer (23), non-small cell lung 
cancer (24), and urological cancer (25). There is little data available however on what 
constitutes a safe interval to surgery after diagnosis. The 62 day interval adopted as a target 
for treatment of most solid tumours in England was selected as a pragmatic figure without 
evidence of beneficial effect for each tumour type. Although there is evidence that late 
diagnosis has a negative effect on outcome in pancreatic cancer, as shown by the low 
resection rate (26), the study shows that following symptomatic presentation delay of up to two 
months prior to resection has no further effect on outcome in pancreatic and bile duct cancer. 
For ampullary cancer however a delay to surgery within the 62 day target period has a 
measurable effect, with some lesions progressing to inoperability and improved outcome of 
the selected cases which remain resectable. This finding has significant implications for 
planning surgery in patients with PC, as the final histological tumour type is not known until 
surgery is completed, and early surgery for these patients is therefore preferable. Also these 
findings suggest that in some patients with inoperable PC the tumour may originate within 
the ampulla, rather than the pancreas. This may have implications for the selection of 
palliative chemotherapy in this patient group. 
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N=266 Cancer Origin p 
Pancreas 
(149) 
Bile duct 
(46) 
Ampulla 
(71) 
Median age (range) 67.9  
(41.3- 82.1) 
65.7  
(43.7-84.1) 
66.2 
(411.2-86.4) 
.312 
Gender (% male) 55 69.6 53.5 .171 
ASA I 6 4 9 .056 
2 84 22 42 
3 44 15 14 
4 1 0 0 
Missing 14 5 6 
Median IS (range) 
(days) 
48 (1-551) 50 (5-294) 51 (14-477) .881 
Median tumour 
size (range) (mm) 
30 (12-70) 22 (10-70) 25 (5-80) .002 
Involved lymph 
nodes (%) 
127 (85.2) 26 (56.5) 40 (56.3) .0001 
Involved resection 
margin (%) 
119 (79.9) 23 (50) 15 (21.1) .0001 
30 day post-
operative mortality 
(%) 
3 (2) 0 3 (4.2) 0.275 
 
Table 1. Interval to surgery and pathological outcome among 266 patients undergoing 
resection of peri-ampullary cancer.  
 
 
  
  
 
 
 
 
 
 
 
Tumour type Exponent 95%  confidence 
interval of 
exponent 
p 
Pancreas (149) 0.927 0.716-1.199 0.562 
Bile duct (46) 0.769 0.397-1.489 0.435 
Ampulla (71) 0.555 0.320-0.963 0.036* 
 
Table 2.  Cox regression analysis of association of interval to surgery with survival of patient 
cohorts, determined by tumour origin. 
  
  
 Tumour Size Nodal status Resection margin status 
 Co-
efficient 
SD p Co-
efficient  
SD p Co-
efficient 
SD p 
Interval to 
surgery (< or 
> median) 
-0.140 0.134 0.232 -0.504 0.514 0.326 -1.486 
 
0.691 
 
0.032* 
 
Gender -0.510 0.119 0.000* 
 
-0.670 0.525 0.202 -0.230 0.646 0.722 
Age -0.017 0.006 0.005* -0.004 0.026 0.878 -0.004 0.033 0.912 
 
Biliary 
obstruction at 
presentation 
-0.161 0.165 0.312 0.846 0.702 0.228 -0.884 0.834 0.289 
 
 
Table 3. Multivariate analysis of potential associations with tumour size, nodal status and 
resection margin status among 71 patients undergoing resection of ampullary cancer 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Number at risk (Pancreatic cancer) 
Years 0 2 4 6 8 
0-30 days 33 11 5 3 2 
30-60 days 69 21 5 2 1 
>60 days 47 12 5 0  
 
 
 
 
 
 
 
 
  
 
 
 
Number at risk (Bile duct cancer) 
Years 0 2 4 6 8 
0-30 days 5 2 1 1 0 
30-60 days 25 14 5 4 0 
>60 days 16 10 2 2 1 
 
 
 
 
  
Number at risk (Ampullary cancer) 
Interval to 
surgery/Years 
0 2 4 6 8 
0-30 days 8 2 1 1 0 
30-60 days 37 22 12 5 2 
>60 days 26 18 7 0  
 
Figure 1. Survival curves of patients undergoing pancreatic head resection for a) pancreatic 
(149), b) bile duct (46) and c) ampullary cancer (71), divided into subsets determined by the 
interval to surgery from initial investigation. 
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